<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019664</url>
  </required_header>
  <id_info>
    <org_study_id>CMG2020-09T</org_study_id>
    <nct_id>NCT05019664</nct_id>
  </id_info>
  <brief_title>Affixus Natural Nail System Humeral Nail PMCF</brief_title>
  <official_title>Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Affixus Natural Nail System Humeral Nail (Implants and Instrumentation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A commercially available product clinical study which aims to confirm the safety, performance&#xD;
      and clinical benefits to the patient of the Affixus Natural Nail upper arm (humerus) bone&#xD;
      nail system for both the implant itself and the instrumentation used during surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objective:&#xD;
&#xD;
      The objectives of this observational, prospective study with optional retrospective&#xD;
      enrollment are to confirm safety, performance and clinical benefits of the Affixus Natural&#xD;
      Nail System Humeral Nail and its instrumentation by analyzing adverse event records,&#xD;
      fracture/osteotomy healing and functional outcome and adverse events.&#xD;
&#xD;
      The safety of the system will be assessed by monitoring the frequency and incidence of&#xD;
      adverse events. Relation of the events to implant, instrumentation and/or procedure should be&#xD;
      specified.&#xD;
&#xD;
      The performance and clinical benefits will be evaluated by assessment of fracture/osteotomy&#xD;
      healing and functional outcome of all enrolled study subjects.&#xD;
&#xD;
      Study Endpoints:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      The primary endpoint is bone union after 12 months since surgery.&#xD;
&#xD;
      Secondary endpoint:&#xD;
&#xD;
      The secondary endpoints will be evaluating functional outcomes (Range of Motion, &amp; American&#xD;
      Shoulder and Elbow Surgeons questionnaire), quality of life questionnaire (EQ-5D-5L),&#xD;
      radiographic findings and adverse events including re-operation of all enrolled study&#xD;
      subjects at the defined follow up time points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Union</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint is bone union after 12 months since surgery. (Bone union defined as no pain or tenderness at the site, and strong enough to allow normal activities.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>12 months</time_frame>
    <description>The Range of Motion (total shoulder motion, active and passive) of the affected and contralateral (right and left) upper arm will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>12 months</time_frame>
    <description>EQ-5D-5L Health Questionnaire is completed by the patient and assesses his/her general health status. The EQ-5D-5L is used to derive a quality of life index used for health economics considerations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Findings</measure>
    <time_frame>12 months</time_frame>
    <description>Postoperative Radiographic Evaluation collects radiographic parameters like bridging callus, visible fracture line, device fracture, device loosening and union status (AP, lateral, and auxiliary view).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse Event Report is completed as needed for each complication which is noted.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Humeral Fractures, Proximal</condition>
  <condition>Humeral Fractures</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Humeral fracture nailing</intervention_name>
    <description>inramedullary nailing designed for fixation and stabilization of fractures or osteotomies of the humerus</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive series of 100 subjects globally implanted with the Affixus Natural Nail System&#xD;
        Humeral Nail for temporary fixation and stabilization of fractures or osteotomies of the&#xD;
        humerus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years or older and skeletally mature.&#xD;
&#xD;
          -  Patient must have either a proximal humeral fracture or humeral shaft fracture&#xD;
             requiring surgical intervention and be eligible for fixation by intramedullary&#xD;
             nailing.&#xD;
&#xD;
          -  Patient has been or is scheduled to be treated with the Affixus Natural Nail System&#xD;
             Humeral Nail.&#xD;
&#xD;
          -  Patient must be able and willing to complete the protocol required follow-up.&#xD;
&#xD;
          -  Patient must have a signed Institutional Review Board/Ethics Committee approved&#xD;
             informed consent. (An Institutional Review Board/Ethics Committee is group that has&#xD;
             been formally designated to review and monitor medical research involving human&#xD;
             subjects.)&#xD;
&#xD;
          -  Patients capable of understanding the surgeon's explanations and following his&#xD;
             instructions, able and willing to participate in the follow-up program and who gave&#xD;
             consent to take part in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distal fracture involving the olecranon fossa.&#xD;
&#xD;
          -  Bone shaft having excessive bow or deformity.&#xD;
&#xD;
          -  A medullary canal obliterated by a previous fracture or tumor.&#xD;
&#xD;
          -  Active or previous infection.&#xD;
&#xD;
          -  Skeletally immature patients.&#xD;
&#xD;
          -  All concomitant diseases that can impair the functioning and the success of the&#xD;
             implant.&#xD;
&#xD;
          -  Patients with mental or neurologic conditions who are unwilling or incapable of giving&#xD;
             proper informed consent and following postoperative care instructions.&#xD;
&#xD;
          -  Patient is a vulnerable subject (prisoner, mentally incompetent or unable to&#xD;
             understand what participation to the study entails, a known alcohol or drug abuser,&#xD;
             anticipated to be non-compliant).&#xD;
&#xD;
          -  Patient known to be pregnant or breast feeding.&#xD;
&#xD;
          -  Likely problems with maintaining follow-up program (e.g. patient with no fixed&#xD;
             address, long distance, plans to move during course of study).&#xD;
&#xD;
          -  Patients who have any condition that would in the judgment of the investigator place&#xD;
             the patient at undue risk or interfere with the study.&#xD;
&#xD;
          -  Not expected to survive the duration of the follow-up program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Achakri, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Director Clinical Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristopher J Krajewski, B.A.</last_name>
    <phone>+41 79 396 94 59</phone>
    <email>Kristopher.Krajewski@zimmerbiomet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darin A Fawley, B.S., M.A</last_name>
    <phone>+1 574 373 4340</phone>
    <email>Darin.Fawley@zimmerbiomet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven - Traumatology Department</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefaan Nijs, M.D.</last_name>
      <phone>+32 16 34 46 66</phone>
      <email>stefaan.nijs@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Elga Nijs</last_name>
      <phone>+32 16 34 23 64</phone>
      <email>elga.nijs@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Julio de Caso, M.D.</last_name>
      <phone>+34 617715500</phone>
      <email>jcaso@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <state>Thurgau</state>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ralph Zettl, M.D.</last_name>
      <phone>+41 52 723 76 81</phone>
      <email>ralph.zettl@stgag.ch</email>
    </contact>
    <contact_backup>
      <last_name>Florian Hess, M.D.</last_name>
      <phone>+41 52 723 76 81</phone>
      <email>florian.hess@stgag.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Humeral Fractures</mesh_term>
    <mesh_term>Shoulder Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This aspect of the study is undecided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

